Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Newer treatments for fibromyalgia syndrome

Authors Richard E Harris, Daniel J Clauw

Published Date December 2008 Volume 2008:4(6) Pages 1331—1342

DOI http://dx.doi.org/10.2147/TCRM.S3396

Published 18 December 2008

Richard E Harris, Daniel J Clauw

Department of Anesthesiology, The University of Michigan, Ann Arbor, MI, USA

Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The lack of understanding of the pathophysiology of fibromyalgia has made this condition frustrating for patients and clinicians alike. The most common symptoms of this disorder are chronic widespread pain, fatigue, sleep disturbances, difficulty with memory, and morning stiffness. Emerging evidence points towards augmented pain processing within the central nervous system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the two drugs that are approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment of fibromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 fibromyalgia patients showed significant improvements relative to placebo. Milnacipran given either once or twice daily at doses up to 200 mg/day was generally well tolerated and yielded significant improvements relative to placebo on measures of pain, patient’s global impression of change in their disease state, physical function, and fatigue. Future studies are needed to validate the efficacy of milnacipran in fibromyalgia.

Keywords: fibromyalgia, pain, pharmacological, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Hepatitis C virus infection and risk of cancer: a population-based cohort study

Lars Haukali Omland, Dora Körmendiné Farkas, Peter Jepsen, et al

Clinical Epidemiology 2010, 2:179-186

Published Date: 24 June 2010

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Jill M Recla

Journal of Pain Research 2010, 3:89-103

Published Date: 22 July 2010

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

Xianchen Liu, Yi Chen, Douglas E Faries, et al

ClinicoEconomics and Outcomes Research 2011, 3:63-72

Published Date: 15 March 2011

Duloxetine in the management of diabetic peripheral neuropathic pain

Ormseth MJ, Scholz BA, Boomershine CS

Patient Preference and Adherence 2011, 5:343-356

Published Date: 19 July 2011

Synthesis and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by blending with chitosan for neural tissue engineering

Naghavi Alhosseini S, Moztarzadeh F, Mozafari M, Asgari S, Dodel M, Samadikuchaksaraei A, Kargozar S, Jalali N

International Journal of Nanomedicine 2012, 7:25-34

Published Date: 4 January 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Predictors of duloxetine adherence and persistence in patients with fibromyalgia

Cui Z, Zhao Y, Novick D, Faries D

Journal of Pain Research 2012, 5:193-201

Published Date: 22 June 2012